JP2020503862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503862A5 JP2020503862A5 JP2019534762A JP2019534762A JP2020503862A5 JP 2020503862 A5 JP2020503862 A5 JP 2020503862A5 JP 2019534762 A JP2019534762 A JP 2019534762A JP 2019534762 A JP2019534762 A JP 2019534762A JP 2020503862 A5 JP2020503862 A5 JP 2020503862A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- pharmaceutical composition
- seq
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 9
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 241000606219 Bacteroides uniformis Species 0.000 claims 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 3
- 229940121652 CTLA-4 inhibitors Drugs 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims 3
- 229940121655 PD-1 inhibitors Drugs 0.000 claims 3
- 230000001580 bacterial Effects 0.000 claims 3
- 241001105998 Bacteroides dorei Species 0.000 claims 2
- 241000186398 Eubacterium limosum Species 0.000 claims 2
- 241000605991 Fusobacterium ulcerans Species 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 2
- 229940121656 PD-L1 inhibitors Drugs 0.000 claims 2
- 241001216709 Parabacteroides gordonii Species 0.000 claims 2
- 241000543747 Parabacteroides johnsonii Species 0.000 claims 2
- 241000789906 Paraprevotella xylaniphila Species 0.000 claims 2
- 241001464924 Phascolarctobacterium faecium Species 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 241001037423 Subdoligranulum sp. Species 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 229920001670 16S ribosomal RNA Polymers 0.000 claims 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 241001135322 Bacteroides eggerthii Species 0.000 claims 1
- 241001148536 Bacteroides sp. Species 0.000 claims 1
- 210000000941 Bile Anatomy 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 241000193464 Clostridium sp. Species 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 210000000416 Exudates and Transudates Anatomy 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 241001674997 Hungatella hathewayi Species 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- 241001072604 Lachnospiraceae bacterium HGA0140 Species 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 241000606210 Parabacteroides distasonis Species 0.000 claims 1
- 241000030714 Parabacteroides goldsteinii Species 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 241000134861 Ruminococcus sp. Species 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 210000001635 Urinary Tract Anatomy 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 206010046885 Vaginal cancer Diseases 0.000 claims 1
- 229960003165 Vancomycin Drugs 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 241001098250 [Clostridium] lavalense Species 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000001069 multicentric Castleman disease Diseases 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000004458 myoma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108010026276 pembrolizumab Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (30)
- Phascolarctobacterium faecium、Fusobacterium ulcerans、Bacteroides dorei、Bacteroides uniformis、Subdoligranulum sp.、Paraprevotella xylaniphila、Parabacteroides johnsonii、Alistipes sp.、Parabacteroides gordonii、Eubacterium limosum、Parabacteroides distasonis、Bacteroides cellulosilyticus、Bacteroides clarus、Anaerostipes caccae、Bacteroides salyersiae、Bacteroides fragilis、Bacteroides uniformis、Bacteroides eggerthii、Clostridium sp.、Parabacteroides goldsteinii、Bacteroides sp.、Lachnospiraceae bacterium HGA0140、Hungatella hathewayi、Clostridium lavalense、Ruminococcus sp.、およびClostridium innocuumからなる群から選択される種の1以上の菌株を含む精製細菌混合物を含む、組成物。
- 精製細菌混合物が、少なくとも2、少なくとも3、少なくとも4、少なくとも5、少なくとも6、少なくとも7、少なくとも8、少なくとも9、少なくとも10、少なくとも11、少なくとも12、少なくとも13、少なくとも14、少なくとも15、少なくとも16、少なくとも17、少なくとも18、少なくとも19、少なくとも20、少なくとも21、少なくとも22、少なくとも23、少なくとも24、少なくとも25、または少なくとも26の菌株を含む、請求項1に記載の組成物。
- Phascolarctobacterium faecium、Fusobacterium ulcerans、Bacteroides dorei、Bacteroides uniformis、Subdoligranulum sp.、Paraprevotella xylaniphila、Parabacteroides johnsonii、Alistipes sp.、Parabacteroides gordonii、Eubacterium limosum、およびParabacteroides distasonisの菌株からなる精製細菌混合物を含む、請求項1に記載の組成物。
- 配列番号1、配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7、配列番号8、配列番号9、配列番号10、および配列番号11と少なくとも99%配列同一の16S rDNA配列を含む菌株からなる精製細菌混合物を含む、医薬組成物。
- 医薬組成物である、請求項1〜3のいずれか一項に記載の組成物。
- 薬学的に許容し得る賦形剤を含む、請求項4または5に記載の組成物。
- 菌株の1以上が、凍結乾燥されている、請求項1〜6のいずれか一項に記載の組成物。
- 免疫チェックポイント阻害剤をさらに含み、ここで、免疫チェックポイント阻害剤が、PD−1阻害剤、PD−L−1阻害剤、またはCTLA−4阻害剤である、請求項1〜7のいずれか一項に記載の組成物。
- 対象においてがんを処置する方法における使用のための、請求項1〜8のいずれか一項に記載の組成物であって、前記方法が、前記組成物をがんを処置するのに有効な量で対象へ投与することを含む、前記組成物。
- がんが、癌、神経膠腫、中皮腫、黒色腫、リンパ腫、白血病、腺癌、乳房がん、卵巣がん、子宮頸部がん、膠芽腫、多発性骨髄腫、前立腺がん、バーキットリンパ腫、頭頸部がん、結腸がん、結腸直腸がん、非小細胞肺がん、小細胞肺がん、食道のがん、胃がん、膵臓がん、肝胆道がん、胆嚢のがん、小腸のがん、直腸がん、腎臓がん、膀胱がん、前立腺がん、陰茎がん、尿道がん、精巣がん、膣がん、子宮がん、甲状腺がん、副甲状腺がん、副腎がん、膵内分泌がん、カルチノイドがん、骨がん、皮膚がん、網膜芽細胞腫、ホジキンリンパ腫、非ホジキンリンパ腫、カポジ肉腫、多中心性キャッスルマン病、AIDS関連の原発性滲出液リンパ腫、神経外胚葉性腫瘍、または横紋筋肉腫である、請求項9に記載の組成物。
- がんが、黒色腫である、請求項10に記載の組成物。
- 方法が、1以上の抗がん剤を投与することをさらに含む、請求項9〜11のいずれか一項に記載の組成物。
- 抗がん剤が、免疫チェックポイント阻害剤であり、ここで、免疫チェックポイント阻害剤が、PD−1阻害剤、PD−L−1阻害剤、またはCTLA−4阻害剤である、請求項12に記載の組成物。
- 方法が、医薬組成物を投与する前に抗生物質を投与することをさらに含む、請求項9〜13のいずれか一項に記載の組成物。
- 抗生物質が、バンコマイシンである、請求項14に記載の組成物。
- 抗がん剤をさらに含む、請求項4に記載の医薬組成物。
- 抗がん剤が、免疫チェックポイント阻害剤である、請求項16に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、PD−1阻害剤である、請求項17に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、ニボルマブである、請求項17に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、ペンブロリズマブである、請求項17に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、CTLA−4阻害剤である、請求項17に記載の医薬組成物。
- 薬学的に許容し得る賦形剤をさらに含む、請求項4に記載の医薬組成物。
- 経口投与のために製剤化されている、請求項4に記載の医薬組成物。
- 腸への送達のために製剤化されている、請求項4に記載の医薬組成物。
- 結腸への送達のために製剤化されている、請求項4に記載の医薬組成物。
- カプセルの形態である、請求項4に記載の医薬組成物。
- 1以上の腸溶性ポリマーを含むpH感応組成物をさらに含む、請求項4に記載の医薬組成物。
- CD8+ T細胞の増殖および/または集積を誘導する、請求項4に記載の医薬組成物。
- 菌株が、凍結乾燥されている、請求項4に記載の医薬組成物。
- 菌株が、粉末形態である、請求項4に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022104670A JP2022140439A (ja) | 2016-12-23 | 2022-06-29 | Cd8+ t細胞の誘導のための組成物および方法 |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438793P | 2016-12-23 | 2016-12-23 | |
US62/438,793 | 2016-12-23 | ||
US201762484607P | 2017-04-12 | 2017-04-12 | |
US62/484,607 | 2017-04-12 | ||
US201762491062P | 2017-04-27 | 2017-04-27 | |
US62/491,062 | 2017-04-27 | ||
US201762574446P | 2017-10-19 | 2017-10-19 | |
US62/574,446 | 2017-10-19 | ||
PCT/JP2017/046232 WO2018117263A1 (en) | 2016-12-23 | 2017-12-22 | Compositions and methods for the induction of cd8+ t-cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022104670A Division JP2022140439A (ja) | 2016-12-23 | 2022-06-29 | Cd8+ t細胞の誘導のための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020503862A JP2020503862A (ja) | 2020-02-06 |
JP2020503862A5 true JP2020503862A5 (ja) | 2021-02-04 |
JP7104921B2 JP7104921B2 (ja) | 2022-07-22 |
Family
ID=62626620
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019534762A Active JP7104921B2 (ja) | 2016-12-23 | 2017-12-22 | Cd8+ t細胞の誘導のための組成物および方法 |
JP2022104670A Pending JP2022140439A (ja) | 2016-12-23 | 2022-06-29 | Cd8+ t細胞の誘導のための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022104670A Pending JP2022140439A (ja) | 2016-12-23 | 2022-06-29 | Cd8+ t細胞の誘導のための組成物および方法 |
Country Status (14)
Country | Link |
---|---|
US (5) | US11167018B2 (ja) |
EP (1) | EP3559209A4 (ja) |
JP (2) | JP7104921B2 (ja) |
KR (1) | KR102564766B1 (ja) |
CN (1) | CN110191946A (ja) |
AU (2) | AU2017381697B2 (ja) |
BR (1) | BR112019013125B1 (ja) |
CA (2) | CA3045098C (ja) |
IL (3) | IL296740B2 (ja) |
MX (1) | MX2019007648A (ja) |
RU (1) | RU2761873C2 (ja) |
TW (1) | TWI821168B (ja) |
WO (1) | WO2018117263A1 (ja) |
ZA (1) | ZA201903327B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104160014A (zh) * | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
IL296740B2 (en) | 2016-12-23 | 2023-09-01 | Univ Keio | Preparations and methods for the induction of CD8-positive t-cells |
WO2019156234A1 (en) * | 2018-02-09 | 2019-08-15 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
CN110496140B (zh) * | 2018-05-18 | 2022-05-31 | 瑞微(深圳)生物科技有限公司 | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 |
CN113015790A (zh) * | 2018-09-10 | 2021-06-22 | 国立研究开发法人理化学研究所 | 含有属于帕拉普氏菌属的细菌作为有效成分的用于抑制胰蛋白酶活性的组合物 |
MA54074A (fr) * | 2018-11-02 | 2022-02-09 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
CN113474448A (zh) * | 2018-11-21 | 2021-10-01 | 陈扎克伯格生物中心公司 | 高复杂度合成肠道细菌群落 |
ES2763874B2 (es) * | 2018-11-30 | 2020-10-13 | Consejo Superior Investigacion | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades |
WO2020118232A1 (en) * | 2018-12-07 | 2020-06-11 | President And Fellows Of Harvard College | Identification of gut bacteria that promote an anti-tumor response to immunotherapy |
MX2021006863A (es) | 2018-12-12 | 2021-09-14 | 4D Pharma Res Limited | Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer. |
US20220378851A1 (en) * | 2019-11-04 | 2022-12-01 | Vedanta Biosciences, Inc. | Compositions and methods for enhancing immune checkpoint inhibitor therapy |
WO2021102313A1 (en) * | 2019-11-22 | 2021-05-27 | Assembly Biosciences, Inc. | Compositions comprising bacterial species and methods related thereto |
US20230002502A1 (en) * | 2019-11-26 | 2023-01-05 | South Australian Health And Medical Research Institute Limited | Methods and products for reducing side effects associated with use of immune agonist antibodies |
WO2021141828A1 (en) * | 2020-01-10 | 2021-07-15 | Assembly Biosciences, Inc. | Compositions comprising bacterial species and methods related thereto |
CA3167386A1 (en) * | 2020-02-12 | 2021-08-19 | Michael Scharl | A bacterial composition for the treatment of cancer |
WO2021221110A1 (ja) * | 2020-04-29 | 2021-11-04 | 学校法人慶應義塾 | Th1細胞及び/又はTh17細胞の増殖又は活性化を誘導する小腸内細菌 |
GB202007452D0 (en) | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
WO2022216670A1 (en) | 2021-04-05 | 2022-10-13 | Vedanta Biosciences, Inc. | Compositions and methods for treating cancer |
CN116676207B (zh) * | 2023-03-14 | 2024-06-04 | 中国海洋大学 | 一种萨利尔斯氏拟杆菌菌株及其在降解制备硫酸软骨素寡糖及透明质酸寡糖中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3249504A (en) | 1962-03-13 | 1966-05-03 | Becton Dickinson Co | Multiple unit tissue culture preparation and method of preparing same |
JP2005529980A (ja) | 2002-06-19 | 2005-10-06 | ネムローゼ・フェンノートシャップ・ニュートリシア | 代謝ストレスを受けている哺乳動物における異化を治療または予防し、同化を促進する方法及び組成物 |
ES2427646T5 (es) * | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
JP6081195B2 (ja) | 2009-05-11 | 2017-02-15 | バーグ エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する腫瘍性障害の診断のための方法 |
MX2012005524A (es) | 2009-11-11 | 2013-04-03 | Procter & Gamble | Cepa de probioticos bifidobacterium. |
US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
CN104160014A (zh) * | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
CN105451561A (zh) | 2013-02-04 | 2016-03-30 | 赛里斯治疗公司 | 组合物和方法 |
IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
MX367109B (es) * | 2013-11-25 | 2019-08-05 | Seres Therapeutics Inc | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. |
US10300137B2 (en) | 2014-04-10 | 2019-05-28 | Riken | Compositions and methods for induction of TH17 cells |
IL251844B2 (en) * | 2014-10-23 | 2024-04-01 | Roussy Inst Gustave | Methods and products for modulation of microbiota composition to improve the effectiveness of cancer treatment with immune checkpoint blockade |
EP3012270A1 (en) | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
TW201717975A (zh) * | 2015-06-01 | 2017-06-01 | 美國芝加哥州立大學 | 藉由控制共生微生物叢來治療癌症 |
IL296740B2 (en) * | 2016-12-23 | 2023-09-01 | Univ Keio | Preparations and methods for the induction of CD8-positive t-cells |
WO2019156234A1 (en) | 2018-02-09 | 2019-08-15 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
-
2017
- 2017-12-22 IL IL296740A patent/IL296740B2/en unknown
- 2017-12-22 EP EP17884311.6A patent/EP3559209A4/en active Pending
- 2017-12-22 MX MX2019007648A patent/MX2019007648A/es unknown
- 2017-12-22 AU AU2017381697A patent/AU2017381697B2/en active Active
- 2017-12-22 RU RU2019123067A patent/RU2761873C2/ru active
- 2017-12-22 US US16/472,937 patent/US11167018B2/en active Active
- 2017-12-22 CA CA3045098A patent/CA3045098C/en active Active
- 2017-12-22 JP JP2019534762A patent/JP7104921B2/ja active Active
- 2017-12-22 BR BR112019013125-6A patent/BR112019013125B1/pt active IP Right Grant
- 2017-12-22 KR KR1020197021069A patent/KR102564766B1/ko active IP Right Grant
- 2017-12-22 WO PCT/JP2017/046232 patent/WO2018117263A1/en active Application Filing
- 2017-12-22 CN CN201780080359.6A patent/CN110191946A/zh active Pending
- 2017-12-22 CA CA3122548A patent/CA3122548A1/en active Pending
- 2017-12-25 TW TW106145484A patent/TWI821168B/zh active
-
2019
- 2019-05-24 US US16/421,557 patent/US10576136B2/en active Active
- 2019-05-24 US US16/421,578 patent/US10695412B2/en active Active
- 2019-05-27 ZA ZA2019/03327A patent/ZA201903327B/en unknown
- 2019-06-20 IL IL267566A patent/IL267566B/en active IP Right Grant
-
2020
- 2020-01-17 US US16/745,642 patent/US11633465B2/en active Active
- 2020-09-24 IL IL277593A patent/IL277593B2/en unknown
-
2021
- 2021-02-19 AU AU2021201076A patent/AU2021201076B2/en active Active
-
2022
- 2022-06-29 JP JP2022104670A patent/JP2022140439A/ja active Pending
-
2023
- 2023-03-10 US US18/182,055 patent/US20240034440A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020503862A5 (ja) | ||
Gamallat et al. | Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model | |
Kiesgen et al. | Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies | |
JP2010110329A5 (ja) | ||
HRP20171653T1 (hr) | Vezna sredstva koja služe ciljano protiv b7-h1 | |
NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
HRP20171749T1 (hr) | Protutijela specifična za claudin 6 (cldn6) | |
HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
JP2017501155A5 (ja) | ||
JP2019506398A5 (ja) | ||
RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
JP2011130770A5 (ja) | ||
JP2016522202A5 (ja) | ||
JP2011103891A5 (ja) | ||
RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
US20220378851A1 (en) | Compositions and methods for enhancing immune checkpoint inhibitor therapy | |
JP2015530989A5 (ja) | ||
Borate et al. | A first-in-human phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma | |
JP2013507954A5 (ja) | ||
Bu et al. | Phase I clinical trial of autologous CLL1 CAR-T therapy for pediatric patients with relapsed and refractory acute myeloid leukemia | |
JP2015506352A5 (ja) | ||
MX2020014166A (es) | Regímenes de dosis para la inhibición dirigida del factor de crecimiento transformante beta (tgf-b) para usarse en el tratamiento de cáncer del tracto biliar. | |
Lu et al. | Efficacy and safety of capecitabine as maintenance therapy after capecitabine-based combination chemotherapy for patients with advanced esophagogastric junction adenocarcinoma. | |
US20230075822A1 (en) | Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors | |
Li et al. | Two-year follow-up results of C-CAR066, a novel anti-CD20 chimeric antigen receptor cell therapy (CAR-T) in relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients after failure of CD19 CAR-T therapy |